<DOC>
	<DOCNO>NCT00768391</DOCNO>
	<brief_summary>The purpose study determine IMC-3G3 safe patient , also determine best dose IMC-3G3 give patient .</brief_summary>
	<brief_title>Study IMC-3G3 Patients With Tumors That Are Not Responding Standard Therapies No Therapy Available</brief_title>
	<detailed_description>The purpose study establish safety profile maximum tolerate dose ( MTD ) anti-PDGFRα monoclonal antibody IMC-3G3 patient advance solid tumor longer respond standard therapy standard therapy available .</detailed_description>
	<criteria>1 . Histopathologicaldocumented , measurable , non measurable , advanced primary tumor recurrent solid tumor lymphoma unresponsive standard therapy standard therapy available . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 2 study entry . 3 . Able provide write informed consent . 4 . Age 18 year old . 5 . Life expectancy &gt; 3 month . 6 . Adequate hematologic function , define : absolute neutrophil count ≥ 1500/mm3 ; platelet count ≥ 100,000/mm3 7 . Adequate hepatic function , define : total bilirubin level ≤ 1.5 x upper limit normal ( ULN ) ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) level ≤ 2.5 x ULN ≤ 5 x ULN know liver metastases 8 . Adequate renal function , define serum creatinine level ≤ 1.5 x ULN . 9 . Uses effective contraception ( per institutional standard ) , procreative potential exists . 10 . Adequate recovery recent surgery , chemotherapy , radiation therapy . 11 . Accessible treatment followup , must treat participate center . 1 . Received chemotherapy therapeutic radiotherapy 28 day prior first dose study medication ongoing side effect ≥ grade 2 due agent administer 28 day earlier . 2 . Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic ; symptomatic congestive heart failure ; unstable angina pectoris , angioplasty , stenting , myocardial infarction 6 month prior first dose study medication ; uncontrolled hypertension ; clinically significant cardiac arrhythmia include limited : multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment asymptomatic sustain ventricular tachycardia ; uncontrolled diabetes ; psychiatric illness/social situation would compromise patient safety limit compliance study requirement 3 . Progressive symptomatic brain metastasis 4 . Has serious nonhealing active wound , ulcer , bone fracture . 5 . Known human immunodeficiency virus positivity . 6 . Major surgical procedure , open biopsy , significant traumatic injury 28 day prior treatment . 7 . Is currently recently use ( 28 day prior ) thrombolytic agent . 8 . Currently use fulldose warfarin ( exception lowdose warfarin maintain patency preexisting , permanent , indwell intravenous [ I.V . ] catheter ; patient receive warfarin , international normalize ratio [ INR ] &lt; 1.5 ) . A patient require heparin exclude . 9 . Undergoes chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function ( cyclooxygenase2 [ COX2 ] inhibitor permit ) . 10 . Has history clinical evidence deep venous arterial thrombosis ( include pulmonary embolism ) 6 month prior first dose study medication . 11 . Has proteinuria ≥ 2+ routine urinalysis 12 . Pregnancy ( confirm serum beta human chorionic gonadotropin ) lactate 13 . Received prior treatment agent target PDGFR ligand receptor 6 week prior first dose study medication . 14 . Received prior treatment monoclonal antibody 6 week prior first dose study medication . 15 . Has history allergic reaction monoclonal antibody therapeutic protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>